CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management

MMWR Recommendations and Reports

Volumn 62, Issue 1, 2013, Pages

  Schillie, Sarah ^a   Murphy, Trudy V ^a   Sawyer, Mark ^b   Ly, Kathleen ^a   Hughes, Elizabeth ^a   Jiles, Ruth ^a   de Perio, Marie A ^c   Reilly, Meredith ^d   Byrd, Kathy ^a   Ward, John W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ADVISORY COMMITTEE; DISEASE TRANSMISSION; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PREVENTION AND CONTROL; PUBLIC HEALTH SERVICE; TRANSMISSION; UNITED STATES;

ADVISORY COMMITTEES; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HEALTH PERSONNEL; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; INFECTIOUS DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; POST-EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84900555870     PISSN: 10575987     EISSN: 15458601     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. US Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;29:50(No. RR-11).
2. Rosenberg JL, Jones DP, Lipitz LR, Kirsner JB. Viral hepatitis: an occupational hazard to surgeons. JAMA 1973;223:395-400.
3. Trinkoff AM, Le R, Geiger-Brown J, Lipscomb J. Work schedule, needle use, and needlestick injuries among registered nurses. Infect Control Hosp Epidemiol 2007;28:156-64.
4. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev 2000;13:385-407.
5. CDC. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR 1982;31:317-22, 27-8.
6. Averhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
7. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-14.
8. CDC. Update on adult immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991; 40(No. RR-12).
9. CDC. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1997;46(No. RR-18).
10. CDC. Viral hepatitis statistics and surveillance. Available at http://www.cdc.gov/hepatitis/statistics/index.htm.
11. CDC. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(No. RR-7).
12. CDC. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR 2008; 57(No. RR-8).
13. CDC. Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. MMWR 2012;61(No. RR-3).
14. CDC. Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR 2005;54(No. RR-9).
15. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR 2006;55(No. RR-16); quiz.
16. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991;40(No. RR-13).
17. CDC. 2012 Case definitions: Nationally notifiable conditions infectious and non-infectious cases. Atlanta, GA: CDC; 2012.
18. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992-1000.
19. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010;202:192-201.
20. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271-8.
21. CDC. National, state, and local area vaccination coverage among children aged 19-35 months-United States, 2011. MMWR 2012;61:689-96.
22. CDC. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR 2012;61:671-7.
23. CDC. Noninfluenza vaccination coverage among adults-United States, 2011. MMWR 2013;62:66-72.
24. Bond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981;1:550-1.
25. Garibaldi RA, Hatch FE, Bisno AL, Hatch MH, Gregg MB. Nonparenteral serum hepatitis: report of an outbreak. JAMA 1972;220:963-6.
26. Werner BG, Grady GF. Accidental hepatitis-B-surface-antigen-positive inoculations: use of e antigen to estimate infectivity. Ann Intern Med 1982;97:367-9.
27. US Department of Labor. Occupational Health and Safety Administration. Available at http://www.osha.gov.
28. University of Virginia Health System. International healthcare worker safety center. Available at http://www.healthsystem.virginia.edu/pub/epinet/home.html.
29. Boal WL, Leiss JK, Sousa S, et al. The national study to prevent blood exposure in paramedics: exposure reporting. Am J Ind Med 2008;51:213-22.
30. Gershon RR, Pearson JM, Sherman MF, et al. The prevalence and risk factors for percutaneous injuries in registered nurses in the home health care sector. Am J Infect Control 2009;37:525-33.
31. Gershon RR, Qureshi KA, Pogorzelska M, et al. Non-hospital based registered nurses and the risk of bloodborne pathogen exposure. Ind Health 2007;45:695-704.
32. Lipscomb J, Sokas R, McPhaul K, et al. Occupational blood exposure among unlicensed home care workers and home care registered nurses: are they protected? Am J Ind Med 2009;52:563-70.
33. Dement JM, Epling C, Ostbye T, Pompeii LA, Hunt DL. Blood and body fluid exposure risks among health care workers: results from the Duke Health and Safety Surveillance System. Am J Ind Med 2004; 46:637-48.
34. CDC. 2000-2012 exposure logs at three healthcare systems in the United States. Personal Communication, Sarah Schillie.
35. Wang S, editor. Hepatitis B collaborative care model: implementation at a community health center. Healthfirst 2011 fall symposium integrating healthcare: planning and systems to improve health outcomes; 2011.
36. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis 1992;12:282-308.
37. Stratton K, Ford A, Rusch E, Clayton EW. Adverse effects of vaccines: evidence and causality. Washington, DC: The National Academies Press; 2012.
38. Ayoola EA, Johnson AO. Hepatitis B vaccine in pregnancy: immunogenicity, safety and transfer of antibodies to infants. Int J Gynaecol Obstet 1987; 25:297-301.
39. Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol 1991;8:227-32.
40. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011;53:68-75.
41. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009;200:1390-6.
42. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999;179:489-92.
43. Alikasifoglu M, Cullu F, Kutlu T, et al. Comparison study of the immunogenicity of different types and dosages of recombinant hepatitis B vaccine in healthy neonates. J Trop Pediatr 2001;47:60-2.
44. Goldfarb J, Baley J, Medendorp SV, et al. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994;13:18-21.
45. Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine 2013;31:2506-16.
46. Bouter KP, Diepersloot RJ, Wismans PJ, et al. Humoral immune response to a yeast-derived hepatitis B vaccine in patients with type 1 diabetes mellitus. Diabet Med 1992;9:66-9.
47. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985;254:3187-9.
48. Wood RC, MacDonald KL, White KE, et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:2935-9.
49. Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005;24:786-92.
50. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007;25:6958-64.
51. Middleman AB, Baker C, Hu DJ, et al. Duration of immunity from hepatitis B vaccine administered soon after birth among 16 to 19 year old youth in the United States. Presented to the Pediatric Academic Societies, Boston, MA, April 29, 2012.
52. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004;23:650-5.
53. Samandari T, Fiore AE, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007;120:e373-81.
54. Advisory Committee on Immunization Practices. Reilly M. Evidence for cost-effectiveness analysis: non-cost related model inputs. Atlanta, Georgia: CDC; 2012. Available at http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun12.pdf.
55. Funderburke PL, Spencer L. Hepatitis B immunity in high risk health care workers. Seven years post vaccination. AAOHN J 2000;48:325-30.
56. McMahon B, editor. 30 year follow-up after Hepatitis B vaccination in adults and children. Technical Viral Hepatitis Prevention Board meeting; Milan, Italy; 2011.
57. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005;142:333-41.
58. Spradling PR, Williams RE, Xing J, Soyemi K, Towers J. Serologic testing for protection against hepatitis B virus infection among students at a health sciences university in the United States. Infect Control Hosp Epidemiol 2012;33:732-6.
59. Stevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992;90:170-3.
60. Tohme RA, Ribner B, Huey MJ, Spradling PR. Hepatitis B vaccination coverage and documented seroprotection among matriculating healthcare students at an academic institution in the United States. Infect Control Hosp Epidemiol 2011;32:818-21.
61. Watson B, West DJ, Chilkatowsky A, Piercy S, Ioli VA. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 2001;19:3164-8.
62. Williams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine 2001;19:4081-5.
63. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011; 18:369-75.
64. Zhu CL, Liu P, Chen T, et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine 2011;29:7835-41.
65. Byrd KB, Lu PJ, Murphy TV. Hepatitis B vaccination coverage among health-care personnel in the United States. Public Health Rep 2013;128:498-509.
66. CDC. Healthy people topics and objectives index. Available at http://www.healthypeople.gov/2020/topicsobjectives2020/default.aspx.
67. CDC. Harriman K. Survey administered to infection preventionists in California healthcare institutions. Atlanta, GA: CDC; 2012.
68. Clemens R, Sanger R, Kruppenbacher J, et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule-results of a post-marketing surveillance. Vaccine 1997;15:349-52.
69. Craven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986;105:356-60.
70. Bertino JS Jr, Tirrell P, Greenberg RN, et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis 1997;175:678-81.
71. Goldwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997;15:353-6.
72. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA 1990;263:1218-22.
73. Osterholm MT, Garayalde SM. Clinical viral hepatitis B among Minnesota hospital personnel: results of a ten-year statewide survey. JAMA 1985;254:3207-12.
74. Tosti ME, editor. Breakthrough HBV infections in vaccinated people: a ten-year surveillance study in Italy. Technical Viral Hepatitis Prevention Board meeting. Milan, Italy; 2011.
75. CDC. Assessment of Hepatitis B vaccination history among healthcare personnel with acute Hepatitis B. CDC Surveillance Project; 2012.
76. CDC. Immunization Information Systems. Available at http://www.cdc.gov/vaccines/programs/iis/index.html.
77. CDC. Immunization Information Systems. Personal communication, Gary Urquhart; 2012.
78. Shi Z, Li X, Ma L, Yang Y. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis. Int J Infect Dis 2010;14:e622-34.
79. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-102.
80. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. JAMA 1985;253:1740-5.
81. Beasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983;3:135-41.
82. Grady GF, Lee VA, Prince AM, et al. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis 1978;138:625-38.
83. Prince AM, Szmuness W, Mann MK, et al. Hepatitis B immune globulin: final report of a controlled, multicenter trial of efficacy in prevention of dialysis-associated hepatitis. J Infect Dis 1978;137:131-44.
84. Prince AM, Szmuness W, Mann MK, et al. Hepatitis B "immune" globulin: effectiveness in prevention of dialysis-associated hepatitis. N Engl J Med 1975;293:1063-7.
85. Seeff LB, Wright EC, Zimmerman HJ, et al. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978;88:285-93.
86. Seeff LB, Zimmerman HJ, Wright EC, et al. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis: a Veterans Administration cooperative study. Gastroenterology 1977;72:111-21.
87. Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin. JAMA 1971;218:1665-70.
88. Wauters JP, Leski M. Delayed hepatitis after treatment with hepatitis B immune serum globulin. BMJ 1976;2:19-20.
89. Zhou F, Euler GL, McPhee SJ, et al. Economic analysis of promotion of hepatitis B vaccinations among Vietnamese-American children and adolescents in Houston and Dallas. Pediatrics 2003;111:1289-96.
90. CDC. Guideline for infection control in health care personnel, 1998. Available at http://www.cdc.gov/hicpac/pdf/infectcontrol98.pdf.
91. Bolyard EA, Tablan OC, Williams WW, et al. Guideline for infection control in healthcare personnel, 1998: Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1998;19:407-63.
92. Enfield KB, Sharapov U, Hall KK, et al. Transmission of hepatitis B virus from an orthopedic surgeon with a high viral load. Clin Infect Dis 2013;56:218-24.